Abstract
Glucocorticoids are widely used to treat inflammatory and malignant diseases. However, many individuals show a lack of therapeutic response and unwanted side-effects. Various known and unknown parameters determine glucocorticoid responsiveness, among them glucocorticoid receptor (GR)-interacting proteins. Several of the proteins interacting with GR also participate in other signal transduction pathways such as the AP-1 pathway and the nuclear factor-kappaB pathway. We suggest that a closer study of GR-interacting proteins may shed new light on mechanisms determining glucocorticoid sensitivity. In this commentary, the general mechanisms of GR action will be addressed and a proteomic-based method to study GR-interacting proteins will be described in brief.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
14-3-3 Proteins
-
Animals
-
Anti-Inflammatory Agents / metabolism
-
Anti-Inflammatory Agents / therapeutic use*
-
Cytosol / metabolism
-
Drug Resistance
-
Electrophoresis, Gel, Two-Dimensional
-
Electrophoresis, Polyacrylamide Gel
-
Inflammation / drug therapy*
-
Inflammation / metabolism
-
Isoelectric Focusing
-
Liver / metabolism
-
MAP Kinase Signaling System / physiology
-
NF-kappa B / metabolism
-
Proto-Oncogene Proteins c-raf / metabolism
-
Rats
-
Receptors, Glucocorticoid / genetics
-
Receptors, Glucocorticoid / metabolism*
-
Signal Transduction / physiology*
-
Tyrosine 3-Monooxygenase / metabolism
Substances
-
14-3-3 Proteins
-
Anti-Inflammatory Agents
-
NF-kappa B
-
Receptors, Glucocorticoid
-
Tyrosine 3-Monooxygenase
-
Proto-Oncogene Proteins c-raf